Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Substantial Shareholding

19 Jun 2008 17:26

RNS Number : 1421X
ReGen Therapeutics PLC
19 June 2008
 
 
19th June 2008
 
REGEN THERAPEUTICS PLC
(“ReGen” or the “Company”; Ticker: (RGT))
 
 
TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES
 
 
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):
 
ReGen Therapeutics Plc
 
2. Reason for the notification:
 
An acquisition or disposal of voting rights
 
3. Full name of person(s) subject to the notification obligation (iii):
 
Andrew Clement Wilson
 
4. Full name of shareholder(s) (if difference from 3):
 
As above
 
5. Date of the transaction and date on which the threshold is crossed or reached (v):
 
18 June 2008
 
6. Date on which issued notified:
 
19 June 2008
 
7. Threshold(s) that is/are crossed or reached:
 
13%
8. Notified details
 
A: Voting rights attached to shares
 
Class/type of share if possible using the ISIN Code GB00B28XMY25
 
Situation Previous to the triggering transaction (vi) –
Number of Shares 1,477,000
Number of Voting Rights (viii) 1,477,000
 
Resulting situation after the triggering transaction (viii) –
Number of Shares 1,495,000
Number of Voting Rights – Direct (x) 1,495,000
Number of Voting Rights – Indirect (xi) N/A
% of voting rights – Direct 13.02%
% of voting rights – Indirect N/A
B: Financial Instruments
Resulting situation after the triggering transaction (xii)
 
Type of financial instrument N/A
 
Expiration date (xiii) N/A
 
Exercise/Conversion Period/Date (xiv) N/A
 
Number of voting rights that may be acquired if the
instrument is exercised/converted N/A
 
% of voting rights N/A
Total (A+B)
 
Number of voting rights 1,495,000
 
% of voting rights 13.02
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):
 
Shares are held in own name
 
Proxy Voting:
 
10. Name of the proxy holder: N/A
 
11. Number of voting rights proxy holder will cease to hold: N/A
 
12. Date on which proxy holder will cease to hold voting rights: N/A
 
13. Additional information: N/A
 
14. Contact name: N/A
 
15. Contact telephone number: N/A
 
 
For further information:
 
Percy Lomax
ReGen Therapeutics Plc
Tel: +44 (0) 207 153 4920
 
Roland Cornish / Felicity Geidt
Beaumont Cornish Limited
Tel: +44(0) 207 628 3396

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKCKDABKDCAD
Date   Source Headline
2nd Mar 201812:09 pmRNSStatement re broker
22nd Jan 20187:00 amRNSPlacing
16th Jan 20187:00 amRNSPlacing
15th Dec 20177:00 amRNSPlacing and Issue of Equity
8th Dec 20177:00 amRNSMilciclib Phase 2a Trial Update
27th Nov 20177:00 amRNSPlacing
23rd Nov 20177:00 amRNSPhase II Clinical Trial Update
20th Nov 20177:00 amRNSSubscription
29th Sep 20177:00 amRNSInterim Results for Six Months Ended 30 June 2017
6th Sep 20177:00 amRNSA Proprietary Oral Formulation of Foralumab
31st Aug 201711:07 amRNSGrant of options - Director's dealing
16th Aug 20177:00 amRNSConversion of outstanding loan notes
28th Jul 20177:00 amRNSPublication of Research Article on Foralumab
19th Jul 20177:00 amRNSInitiation of a Phase IIa Clinical Trial
12th Jul 20177:00 amRNSProposed changes to CLNs and Warrant Terms
29th Jun 201711:21 amRNSResult of AGM
12th Jun 20177:00 amRNSAppointment of Dr Kunwar Shailubhai as CEO
8th Jun 201710:02 amRNSNOTIFICATION OF MAJOR INTEREST IN SHARES
8th Jun 20178:14 amRNSBcl-3 pre-clinical update and Director's dealing
1st Jun 20177:00 amRNS2016 Annual Report and Accounts and notice of AGM
23rd May 20177:00 amRNSFinancial Results for Year Ended 31 December 2016
24th Apr 20177:14 amRNSAnnounces Approval of a Phase II Clinical Trial
21st Apr 20177:00 amRNSAnnounces Publication of Milciclib Clinical Trial
24th Mar 20177:00 amRNSExercise of Warrants & Issue of Equity
14th Mar 20177:00 amRNSArun Sanyal appointed to Scientific Advisory Board
16th Jan 20177:00 amRNSWarrant Expiry - Reminder
3rd Jan 20177:00 amRNSTiziana Life Sciences in-licenses NI-1201
16th Nov 20167:00 amRNSNew Data with Foralumab
7th Nov 201612:29 pmRNSGrant of options
29th Sep 20167:00 amRNSHalf-year Report
15th Sep 20167:00 amRNSConfirmation of Capital Reduction
18th Aug 20167:00 amRNSChange of Registered Office
18th Jul 20167:00 amRNSTiziana acquires a unique bio-repository
30th Jun 201612:47 pmRNSResult of AGM
29th Jun 20167:00 amRNSIssue of Equity
10th Jun 201610:18 amRNSGrant of options and realisation bonus
7th Jun 20167:00 amRNSFinal Results
1st Jun 20167:00 amRNSPartnership with Cardiff Researchers Wins Award
19th May 20167:00 amRNSJournal review of anti - CD3 monoclonal antibodies
4th May 20167:00 amRNSAppointment of Dr. Robert Evans
28th Apr 20167:00 amRNSExercise of Warrants & Issue of Equity
4th Apr 20167:00 amRNSChief Financial Officer Appointed
15th Mar 20167:00 amRNSCo-Founder and NED Prof Chris McGuigan Passes Away
16th Feb 20164:40 pmRNSSecond Price Monitoring Extn
16th Feb 20164:35 pmRNSPrice Monitoring Extension
13th Jan 20167:00 amRNSFund raising
11th Jan 20167:00 amRNSDevelopment plans for foralumab & SAB appointments
8th Jan 20167:00 amRNSUpdate on Tiziana's Bcl-3 inhibitor
9th Dec 20158:00 amRNSAppoints James F. Tripp as Chief Operating Officer
8th Dec 20157:00 amRNSFund raising

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.